AbbVie (ABBV) – Investment Analysts’ Recent Ratings Updates

A number of research firms have changed their ratings and price targets for AbbVie (NYSE: ABBV):

• 10/13/2026 – AbbVie had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $280.00 price target on the stock.
• 10/9/2026 – AbbVie had its “buy” rating reaffirmed by Guggenheim. They now have a $288.00 price target on the stock.
• 10/8/2026 – AbbVie was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
• 10/8/2026 – AbbVie had its price target raised by JPMorgan Chase & Co. from $285.00 to $300.00. They now have an “overweight” rating on the stock.
• 10/8/2026 – AbbVie had its price target raised by Cantor Fitzgerald from $285.00 to $290.00. They now have an “overweight” rating on the stock.
• 10/7/2026 – AbbVie had its price target raised by Morgan Stanley from $296.00 to $310.00. They now have an “overweight” rating on the stock.
• 10/6/2026 – AbbVie had its price target raised by Scotiabank from $280.00 to $320.00. They now have an “outperform” rating on the stock.
• 10/6/2026 – AbbVie had its price target raised by UBS Group AG from $260.00 to $275.00. They now have a “neutral” rating on the stock.
• 10/6/2026 – AbbVie had its price target raised by Scotiabank from $280.00 to $320.00. They now have a “sector outperform” rating on the stock.
• 9/16/2026 – AbbVie had its “overweight” rating reaffirmed by Cantor Fitzgerald. They now have a $240.00 price target on the stock, down from $250.00.
• 9/10/2026 – AbbVie had its price target raised by HSBC Holdings plc from $300.00 to $315.00. They now have a “buy” rating on the stock.
• 9/8/2026 – AbbVie had its “buy” rating reaffirmed by Bank of America Corporation.
• 9/8/2026 – AbbVie had its price target raised by Bank of America Corporation from $276.00 to $282.00.

AbbVie Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be issued a dividend of $1.73 per share. The ex-dividend date of this dividend is Thursday, October 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.4%. AbbVie’s payout ratio is presently 195.48%.

Insider Buying and Selling at AbbVie

In other news, EVP Nicholas Donoghoe sold 32,710 shares of the company’s stock in a transaction dated Friday, August 14th. The stock was sold at an average price of $250.00, for a total transaction of $8,177,500.00. Following the sale, the executive vice president directly owned 74,430 shares in the company, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 0.06% of the stock is currently owned by corporate insiders.

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines and other healthcare products. Its portfolio focuses on immunology, oncology, neuroscience, aesthetics and eye care, serving patients and healthcare providers in markets around the world.

The company’s key products include immunology medicines such as Skyrizi and Rinvoq; neuroscience treatments including Vraylar, Ubrelvy and Qulipta; and oncology products such as Imbruvica and Venclexta.